TELEROUTE
17.9.2020 10:02:04 CEST | Business Wire | Press release
The activity registered on the Teleroute Freight Exchange has been experiencing an upward trend for several weeks following the strong increase in demand for their solution during the Coronavirus crisis, demonstrating the resilience and anti-cyclical nature of one of Europe’s leading freight exchanges.
After the initial shock to the European market due to the Coronavirus, the Teleroute Freight Exchange, that together with 123Cargo and Wtransnet form one of the largest European transport collaboration networks, confirms the return of activity with a notable upturn in the number of freight offers in recent weeks , placing the activity at pre-coronavirus level and even higher in the last weeks of July, exhibiting none of the typical seasonal slowdown.
The most difficult moment for the transportation industry due to the crisis took place in April, where the complete stoppage of industrial activity throughout Europe caused freight volume to drop dramatically. This period was then followed by a second disrupted supply chain period where freight forwarders and carriers, looking for new routes for new volumes, turned to Teleroute to manage demand and the number of new users on Teleroute grew by 1,200.
Speaking about this trend, Fabrice Douteaud, COO of Teleroute, said: “We are very proud of the resilience shown by the transport & freight forwarding companies by continuing their important work during these very difficult times. We have experienced an exceptional demand for our freight exchange during this crisis, a proof of the value we bring to the market: facilitating the collaboration of transport professionals.”
France, the driving force behind the recovery of freight offers in Europe
After the month of April with volume below average, we are in the middle of the summer with a very notable recovery of the freight offers on Teleroute with France as the country of origin, which has doubled.
This leaves us with an activity in July that has far exceeded the monthly average number of published freight offers, mainly in the domestic market (90% of volumes) and in exports to Belgium, Germany and Spain in equal parts.
On the other hand, if we look at imports, the numbers are even better, in the last two months we find volumes well above the usual and that shows the recovery of the main countries that send merchandise to France: Italy, which leads the ranking with 37% of freight offers; Germany (29%), Belgium (23%) and Spain (7%).
Italy doubles its transport activity in July thanks to exports
Regarding the data obtained from the freight offers published on Teleroute originating in Italy, one of the countries most affected by the pandemic, we find a surprising recovery in July where the volume has doubled thanks to the reactivation of transactions with France, which account for 57% of Italian exports. Germany with 18% and Spain with 15% close the top 3.
In relation to inbound freight, the transalpine country doubled the number of import offers in July compared to previous months, placing activity above the average in 2019 and only slightly lower than the months with the highest activity on the freight exchange. A comeback led by the flow of goods with France, with 40% of the freight offers published, and Germany (15%) as the main countries offering freight to the Italian market.
Huge growth in the German domestic transport market
Focusing on Germany , another of the European economy's main drivers, we observed a strong rebound in activity in July with 25% above the monthly average in 2019, the domestic market's upward growth, which was already palpable in June, and accounting for 50% of the freight offers with Germany as origin and/or destination.
The other freight offers, are divided into 28% imports, mainly from Italy and France, and exports (remaining 22%) whose main destinations are France and the Netherlands.
Numbers that, in accordance with the offers registered in Teleroute, place the European transport market that Teleroute serves, already back to normal in practically the entire region and, on the current trajectory, will be performing ahead of 2019 for the remainder of the year.
Alpega Group
End-to-End Transportation software
Alpega Group is a leading global logistics software company offering modular solutions that cover all transportation and logistics complexity needs. By bringing together the best solutions and market expertise, the Alpega Group has created the transportation industry’s only scalable end-to-end software suite.
Alpega TMS empowers transport professionals to manage the logistics and supply chain processes, it transforms global and local supply chains into collaborative ecosystems, bringing together all parties involved. Alpega TMS’s unique scalability and best-in-breed standalone solutions ensure shippers benefit from a system that evolves alongside their needs, regardless of the complexity of their logistics processes. Our freight procurement solution, TenderEasy, provides a world-class solution for sourcing transportation providers across air, land and sea. In terms of freight exchanges, 123Cargo, Teleroute and Wtransnet are leading European marketplaces designed to match spot shipments and truck capacity.
These platforms and the data which flows through them, alongside our 30+ years’ experience in transportation lets us enable businesses to optimize their supply chain planning and execution while benefitting from lower costs and higher visibility. All of Alpega’s solutions combine to create added value for customers. Our community of 80,000 carriers and 200,000 members are electronically connected every day to successfully manage critical transport processes. Alpega is present in 80 countries worldwide and employs 500 people with 31 different nationalities.
More information can be found at www.alpegagroup.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200917005113/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
